VIP · Research brief

VIP (Vasoactive Intestinal Peptide): Mechanism, Research & COAs

Real Peptides Research TeamEditorial

Updated September 5, 20269 min read

55 WORDS

Short answer

VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide in the secretin–glucagon family, first isolated from mammalian intestinal tissue in the early 1970s and later found throughout nerves, gut and immune cells. Laboratory research examines its VPAC1 and VPAC2 receptor signaling, circadian timing, immune modulation and gastrointestinal biology. It is handled strictly as a research-use-only material.

Key takeaways

VIP is a 28-amino-acid neuropeptide of the secretin–glucagon–PACAP family, first isolated from mammalian intestinal tissue in the early 1970s and later found in enteric neurons, the suprachiasmatic nucleus, lung, vasculature and immune cells.
Its reported mechanism runs through the class B G-protein-coupled receptors VPAC1 and VPAC2, largely via Gs-coupled adenylate cyclase, cAMP and PKA signaling, with lower-affinity interaction at PAC1.
Published work spans circadian neurobiology, immune and inflammatory signaling, gastrointestinal and mucosal biology, neurodegeneration models, and tissue-repair models — most of it preclinical and hedged.
Clinical literature on VIP is dominated by VIP-secreting tumors (VIPomas and rarer neural-crest tumors), which describe what pathological VIP excess looks like rather than validating any research protocol.
Native VIP is reported to be short-lived in circulation, which shapes both handling practice and interpretation of experimental designs.
Material described here is for research use only; it is not FDA-approved for the applications discussed, and batch-level COAs with HPLC purity and mass-spec identity are the baseline documentation researchers assess.

What VIP Is and Where It Came From

Vasoactive intestinal peptide was originally purified from intestinal extracts during the search for factors that relaxed vascular smooth muscle — hence the name. What began as a gut hormone candidate turned out to be a widely distributed neuropeptide. It is now described as a principal transmitter of non-adrenergic, non-cholinergic enteric neurons, and it is expressed in the suprachiasmatic nucleus of the hypothalamus, cerebral cortex, airway and vascular nerve fibers, and several immune cell populations.

Structurally, VIP belongs to the secretin–glucagon superfamily, which also includes PACAP, GHRH, secretin and glucagon-like peptides. Its closest relative is PACAP, with which it shares roughly two-thirds sequence identity in the overlapping region — a relationship that explains why the two peptides share receptors and why selective pharmacology is difficult to achieve without engineered analogs.

Research material is produced by solid-phase peptide synthesis rather than extraction, then purified by preparative HPLC and lyophilized, typically as an acetate salt. A synthetic version of the native sequence has also been developed as an investigational drug candidate under a separate generic name; that clinical development history is distinct from research-grade peptide material and does not confer approved status on it.

Reported Mechanism of Action

VIP signals through two class B G-protein-coupled receptors, VPAC1 and VPAC2, and interacts with lower affinity at the PACAP-preferring PAC1 receptor. Both VPAC subtypes are principally Gs-coupled: receptor occupancy is reported to activate adenylate cyclase, raise intracellular cAMP, and engage protein kinase A and CREB-dependent transcription. Secondary coupling to phospholipase C and other pathways has been described in some cell types, which is one reason effects appear tissue-dependent rather than uniform.

Receptor	Reported distribution	Commonly described signaling role
VPAC1	Lung epithelium, intestinal mucosa, T lymphocytes, liver, CNS	cAMP/PKA activation; described in epithelial secretion and immune cytokine modulation
VPAC2	Suprachiasmatic nucleus, smooth muscle, mast cells, pancreatic islets	cAMP/PKA activation; associated with circadian synchronization and smooth-muscle relaxation
PAC1	CNS, adrenal medulla, sympathetic ganglia	PACAP-preferring; VIP interacts at substantially lower affinity

Functionally, the literature associates VIP signaling with vasodilation and smooth-muscle relaxation, epithelial water and electrolyte secretion, neuronal coupling in the circadian pacemaker, and a broadly anti-inflammatory shift in immune signaling — including reported suppression of NF-κB-driven proinflammatory cytokines and reported promotion of regulatory T-cell phenotypes in cell and animal systems. Native VIP is also reported to be short-lived in plasma, on the order of minutes, because it is rapidly cleaved by circulating and membrane-bound peptidases. That instability is a recurring theme in the analog-design literature and a practical consideration in experimental design.

What the Research Literature Examines

Circadian neurobiology

Some of the most consistent findings involve VIP-expressing neurons in the suprachiasmatic nucleus, where VPAC2 signaling is described as a key coupling mechanism that keeps individual clock neurons synchronized and gates photic input. Rodent work published in the mid-2020s has extended this to behavior, reporting that suprachiasmatic VIP neurons mediate a light-induced transient forgetting phenomenon — an example of clock circuitry influencing memory retrieval rather than sleep alone. These are animal findings and have not been shown to translate directly.

Immune and inflammatory signaling

A large preclinical body of work characterizes VIP as an endogenous modulator of innate and adaptive immunity, with reported effects on macrophage polarization, dendritic-cell maturation and cytokine balance in cultured cells and rodent inflammation models. A 2025 nanoparticle-delivery study in tendon repair models reports VIP contributing to immune modulation and stem-cell behavior at the injury site, illustrating current interest in delivery vehicles that compensate for the peptide's short half-life. Evidence remains preclinical.

Gastrointestinal and mucosal biology

VIP's original home territory remains active. Work published in the mid-2020s reports that neuronal VIP shapes intestinal stem cell activity and mucosal immunity in animal models, positioning enteric neurons as regulators of epithelial renewal. Separate ex vivo studies using mouse ileal preparations implicate VIP in the depressant effect of glucagon-like peptide-2 on neurally induced contractile responses — a mechanistic, tissue-bath level observation rather than a clinical result.

Neurodegeneration models

A 2025 review argues for a role of VIP in Parkinson's disease biology, drawing on reported neuroprotective and anti-inflammatory observations in cellular and rodent systems. Reviews of this kind synthesize preclinical signals and hypotheses; they do not establish clinical benefit, and no conclusion about human outcomes should be drawn from them.

Clinical endocrinology and VIP excess

The best-characterized human literature on VIP concerns pathological over-secretion. Case reports and a 2019 review describe VIP-secreting tumors — VIPomas of pancreatic origin, and rarer presentations including a VIP-secreting pheochromocytoma and a pediatric VIP-secreting neuroblastoma — which classically present with profuse secretory diarrhea, hypokalemia and achlorhydria. For researchers, this literature is informative in a specific way: it maps what sustained, unregulated VIP receptor activation does at the level of gut secretion and electrolyte handling, and it underlines that VIP is a potent signaling molecule rather than an inert peptide.

Chronic multi-symptom illness contexts

VIP is frequently discussed in online and clinical-community settings in connection with chronic inflammatory response syndrome, mast cell activation, mold-exposure illness and fibromyalgia. Published support in these areas is limited, largely observational or protocol-based rather than randomized, and evidence remains preliminary. The hub's dedicated articles on CIRS, MCAS and fibromyalgia describe what has and has not been published, and where the reasoning is extrapolated from mechanism rather than from outcome data.

Laboratory Handling in General Terms

VIP is provided as a lyophilized powder and is treated as a moisture-sensitive, oxidation-sensitive peptide. General laboratory practice described in peptide handling references includes:

Keeping the sealed lyophilate cold and desiccated, protected from light, and allowing vials to equilibrate to room temperature before opening to limit condensation onto the powder.
Reconstituting with an appropriate sterile diluent, directed gently down the vial wall, then swirling rather than shaking — vigorous agitation promotes foaming and denaturation at the air–liquid interface.
Aliquoting reconstituted solution into single-use volumes to avoid repeated freeze–thaw cycles, which are a common source of unexplained potency drift between experiments.
Using low-binding labware where feasible, since small peptides adsorb to glass and untreated plastic, and recording diluent identity, concentration and preparation date alongside the lot number.
Treating reconstituted material as considerably less stable than the dry form and planning experimental timelines accordingly.

Specific concentrations, volumes and reconstitution arithmetic are covered in the dedicated reconstitution and storage articles in this hub. No amounts are given here, and none of this constitutes guidance for use in humans or animals outside a properly reviewed research setting.

Regulatory and Research-Use Status

VIP is not FDA-approved for any of the applications discussed on this page. It is not a dietary ingredient, not a compounded prescription product in this form, and not intended for diagnostic or therapeutic use. Research-grade peptide material is made available for laboratory research only, to be handled by qualified personnel under appropriate institutional oversight and, where animals or human subjects are involved, under the relevant ethics approvals. Statements in the published literature describe experimental observations; they are not claims about what this material does in people. Anyone evaluating VIP for a study should verify local regulatory requirements before beginning work.

How Research Groups Evaluate Material Quality

Because peptide identity and purity vary widely between sources, documentation matters more than marketing language. The evaluation checklist most laboratories apply includes:

Batch-specific COA. A certificate tied to the exact lot number on the vial — not a generic or representative document reused across production runs.
HPLC purity chromatogram. Reverse-phase HPLC with a visible trace, integration table and method conditions, so the main peak and any impurity shoulders can be assessed rather than accepted as a single number.
Mass spectrometry identity. An observed mass consistent with the theoretical monoisotopic or average mass of the 28-residue sequence, confirming that the correct molecule was made.
Peptide content versus net weight. Amino acid analysis or nitrogen determination distinguishes actual peptide mass from counterion and residual water — a frequent source of concentration error.
Counterion and residual solvent notes. Acetate versus TFA salt form can influence cell-based assays; residual TFA in particular has documented effects in some systems.
Third-party testing and traceability. Independent laboratory verification, plus a paper trail linking synthesis, purification and release testing to the vial in hand.

Dedicated articles in this hub walk through reading a COA line by line, verifying purity claims, and documenting peptide provenance for reproducible research records.

Where the Open Questions Are

Several gaps define the current state of VIP research. First, receptor selectivity: most reported effects cannot be cleanly attributed to VPAC1 versus VPAC2 without engineered analogs or conditional genetic models, so mechanism claims are often composite. Second, delivery and stability: native VIP's rapid degradation means that exposure in a given experiment may bear little resemblance to the concentrations implied by a nominal amount, which complicates cross-study comparison. Third, translation: the immune, circadian, gastrointestinal and neuroprotective findings sit overwhelmingly in cell culture and rodent systems, and the human literature is dominated by tumor-associated VIP excess rather than controlled administration studies. Fourth, biomarker questions — whether circulating or tissue VIP levels track meaningfully with any inflammatory or circadian phenotype — remain unsettled and are complicated by assay variability.

How This Hub Is Organized

The articles beneath this page fall into four clusters: mechanism and background (receptor pharmacology, half-life and stability, why the peptide attracts research interest); research-area deep dives (circadian, inflammation, CIRS and MCAS contexts, fibromyalgia, mold-exposure literature); protocol and handling references (reconstitution, storage after reconstitution, concentration math, delivery-route comparisons, combination research); and quality assurance (reading a COA, verifying purity, documenting provenance, community-reported experience and its limitations). Each is written in the same research-use framing as this overview.

Research-grade VIP (Vasoactive Intestinal Peptide): Real Peptides supplies VIP (Vasoactive Intestinal Peptide) for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore VIP (Vasoactive Intestinal Peptide) research on Real Peptides

The articles below go deeper on the questions researchers ask most about VIP (Vasoactive Intestinal Peptide).

Research questions

Research timelines & mechanisms

Buying & quality

Stacks & comparisons

Reconstitution, storage & handling

Safety & side effects

References

Peer-reviewed sources on VIP (Vasoactive Intestinal Peptide) indexed in PubMed, listed for research context. Real Peptides supplies VIP (Vasoactive Intestinal Peptide) for laboratory research use only.

Vasoactive Intestinal Peptide-Secreting Pheochromocytoma: A Case Report and Review of Literature. AACE clinical case reports, 2022. PMID 35959082. doi:10.1016/j.aace.2022.03.003
Vasoactive Intestinal Peptide-Secreting Tumors: A Review. Pancreas, 2019. PMID 31609932. doi:10.1097/MPA.0000000000001402
Neuronal VIP shapes intestinal stem cell activity and mucosal immunity. Cell stem cell, 2026. PMID 41795422. doi:10.1016/j.stem.2026.02.001
Nanoparticle-Driven Tendon Repair: Role of Vasoactive Intestinal Peptide in Immune Modulation and Stem Cell Enhancement. ACS nano, 2025. PMID 40184556. doi:10.1021/acsnano.4c16917
Contribution of Vasoactive Intestinal Peptide to the Depressant Effects of Glucagon-like Peptide-2 on Neurally Induced Contractile Responses in Mouse Ileal Preparations. International journal of molecular sciences, 2025. PMID 41465229. doi:10.3390/ijms262411797
Vasoactive Intestinal Peptide: A Neuropeptide that Plays an Important Role in Parkinson's Disease. Current neuropharmacology, 2025. PMID 40353414. doi:10.2174/011570159X374501250425045109
Suprachiasmatic Nucleus Vasoactive Intestinal Peptide Neurons Mediate Light-induced Transient Forgetting. Neuroscience bulletin, 2025. PMID 40670769. doi:10.1007/s12264-025-01456-7
Vasoactive Intestinal Polypeptide Secreting MS Neuroblastoma. Journal of Indian Association of Pediatric Surgeons, 2024. PMID 39691933. doi:10.4103/jiaps.jiaps_104_24

Questions

VIP binds the class B G-protein-coupled receptors VPAC1 and VPAC2 with comparable affinity, and interacts with the PACAP-preferring PAC1 receptor at much lower affinity. Because it does not strongly discriminate between VPAC1 and VPAC2, most reported effects reflect combined signaling. Research groups separating the two subtypes generally rely on engineered selective analogs, receptor knockout models or subtype-selective antagonists rather than on native VIP alone.

PACAP and VIP are structurally related members of the same peptide superfamily, sharing roughly two-thirds sequence identity in the overlapping region. Both activate VPAC1 and VPAC2, but PACAP also binds the PAC1 receptor with high affinity, whereas VIP does not. That difference underlies much of their divergent pharmacology in neuronal and adrenal systems, and it is a common design consideration when interpreting overlapping experimental results.

Native VIP is reported to be cleared from circulation within minutes, as circulating and membrane-bound peptidases cleave it rapidly. Consequently, the concentration a tissue actually experiences may differ substantially from the nominal amount introduced, which complicates dose–response interpretation and cross-study comparison. This is why much of the current literature explores stabilized analogs, sustained-release formulations and nanoparticle delivery vehicles rather than the unmodified peptide.

VIPomas are rare neuroendocrine tumors that secrete VIP autonomously, classically producing watery diarrhea, hypokalemia and achlorhydria. Reviews and case reports also describe VIP secretion from pheochromocytoma and neuroblastoma. This literature is the main human dataset on sustained VIP receptor activation, and it illustrates how potent the peptide's effects on intestinal secretion and electrolyte handling can be when signaling is unregulated.

No. VIP is not FDA-approved for the research applications discussed here, and published preclinical findings do not constitute evidence of clinical benefit. Research-grade material is intended for laboratory research only, under appropriate institutional oversight. A synthetic version of the sequence has been investigated as a drug candidate in separate clinical programs, but that development history does not confer approved status on research material.

At minimum: the specific lot number, a reverse-phase HPLC chromatogram with integration data and method conditions, mass spectrometry confirming a mass consistent with the 28-residue sequence, peptide content versus net weight, counterion identity, water content, and the testing date. Batch-specific documents — ideally with third-party verification and a traceable link from synthesis to vial — are what allow independent laboratories to reproduce results.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA